AstraZeneca Pharma India gets CDSCO approval for breast cancer drug Datverzo

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹8984.50

prior close

₹9032.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+1.1% vs market

Pharmaceuticals peers, median of 152sector-0.5%+1.2% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.2

15m

-0.1

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8-0.3+1.1-0.5+1.2

Next day

+0.7+0.9-0.2+0.5+0.2

+1.8+2.3-0.5+1.0+0.8

+1.6+2.4-0.8+1.1+0.5

+2.0+1.8+0.2+0.9+1.1

+0.5+1.3-0.8+0.6-0.1

-0.2+0.4-0.7-0.3+0.0

15d

-7.1-1.1-6.0-0.3-6.9

-7.4-3.3-4.0-2.6-4.8

-1.4-0.5-0.9-2.4+1.0

-5.6-8.2+2.5-9.0+3.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has received approval from CDSCO to import and distribute a new drug called Datopotamab Deruxtecan (brand name Datverzo) in India. It is meant for adult patients with a specific type of advanced breast cancer (HR-positive, HER2-negative) who have already received prior endocrine therapy and chemotherapy. This paves the way for marketing the drug in India, subject to other statutory approvals.

Likely market impact

Positive for the company as it expands its oncology portfolio in India with a new breast cancer drug, offering potential revenue upside.